Johann de Bono from Royal Marsden gives a summary of the PCa sessions at the European Society for Medical Oncology [ESMO] meeting [1]. de Bono is at the center of things these days. For instance, his name is on numerous Abiraterone & Enzalutamide papers.
The summary is intended for doctors, but many here will know enough to be able to follow much of it. And the text is useful for those who missed something in the first pass - it is on 2 pages.
As of now, "for patients with M1 {metastatic} prostate cancer at diagnosis, we have two standards of care: LHRH analog and docetaxel, and LHRH analogs and abiraterone. The data presented at this meeting would indicate that both are entirely satisfactory options, and I think that the patient should have the data explained to them and be allowed to choose whether to have one drug or the other at diagnosis."
Interestingly, he says that "I do not endorse giving both abiraterone and enzalutamide." I wonder why?
-Patrick